3SBioTRSBF -2.27%90 Days Payable is 58.94 as of Dec. 2025, which is 9% below its 10-year median of 64.76. GuruFocus rates TRSBF with a GF Score™ of 90/100 and a GF Value™ of $1.61 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 700 Biotechnology companies, 3SBio ranks worse than 64.57% on this metric.
3SBio's average Accounts Payable for the
six
months ended in Dec. 2025 was $32 Mil. 3SBio's Cost of Goods Sold for the
six
months ended in Dec. 2025 was $101 Mil.
Hence, 3SBio's Days Payable for the
six
months ended in Dec. 2025 was 58.94.
The historical rank and industry rank for 3SBio's Days Payable or its related term are showing as below:
TRSBF'
s Days Payable Range Over the Past 10 Years
Min: 43.42 Med: 64.76 Max: 89.11
Current: 57.42
During the past 12 years, 3SBio's highest Days Payable was 89.11. The lowest was 43.42. And the median was 64.76.
TRSBF's Days Payable is ranked worse than 64.57% of 700
companies
in the Biotechnology industry
Industry Median: 113.1
vs TRSBF: 57.42
3SBio's Days Payable
increased
from Dec. 2024 (51.20) to Dec. 2025 (58.94).
It may suggest that 3SBiodelayed paying its suppliers.
3SBio Days Payable Related Terms
3SBio Days Payable Historical Data
* Premium members only.
The historical data trend for 3SBio's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TRSBF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, 3SBio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3SBio Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3SBio's Days Payable distribution charts can be found below:
* The bar in red indicates where 3SBio's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
3SBio's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
3SBio (TRSBF) has a Days Payable of 58.94 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on 3SBio and its competitors. This is near median its historical median of 64.76. Over the past decade, 3SBio's Days Payable has ranged from 43.42 to 89.11. According to the industry distribution chart, 3SBio ranks #452 out of 700 companies in the Biotechnology industry, placing it in the top 64.6%.
Is 3SBio's Days Payable too high?
3SBio's current Days Payable of 58.94 is near median its 10-year median of 64.76. Over the past 10 years, this metric has ranged from a low of 43.42 to a high of 89.11. The Biotechnology industry median Days Payable is 113.10. 3SBio's value of 58.94 is 47.9% below this industry median. Based on the distribution chart, 3SBio ranks #452 out of 700 companies in the Biotechnology industry, which is below the industry midpoint. Overall, 3SBio has a GF Score™ of 90/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3SBio ranks #452 out of 700 companies for Days Payable. This places 3SBio in the lower half of its industry. The industry median Days Payable is 113.10. 3SBio's value of 58.94 is 47.9% below this benchmark. Historically, 3SBio's own Days Payable has ranged from 43.42 to 89.11 over the past decade. While the company's 10-year median is 64.76 vs. the industry median of 113.10, 3SBio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 3SBio's current Days Payable of 58.94 is 47.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on 3SBio and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 3SBio's current Days Payable is 58.94, which is near median its own 10-year median of 64.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (TRSBF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.61, compared to a current price of $2.15 — trading 33.5% above its estimated fair value. The current Days Payable is 58.94, which is near median its 10-year median of 64.76 and 47.9% below the Biotechnology industry median of 113.10. 3SBio's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For 3SBio (TRSBF), the current Days Payable is 58.94 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3SBio (TRSBF) Overvalued in 2026?
Based on GuruFocus' analysis, 3SBio stock appears to be overvalued.
The current stock price of $2.15 is trading 33.5% above its estimated GF Value™ of $1.61.
GuruFocus considers 3SBio to be Significantly Overvalued.
Key valuation signals for TRSBF:
Days Payable: 58.94 (near median its 10-year median of 64.76)
GF Value™: $1.61 vs. price of $2.15 (33.5% above fair value)
Industry Position: 47.9% below the Biotechnology median (#452 of 700)
No single metric tells the full story. See the TRSBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
90GF Score
Get the complete analysis for TRSBF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRSBF has been successfully added to your 
